# Divarasib

Source: https://onco.cc/drugs/divarasib/  
OnCo record `divarasib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Divarasib is Roche's KRAS G12C pill, the first to beat the two approved KRAS drugs head-to-head (July 2026).

## Summary

Covalent G12C inhibitor with ~5-20-fold greater potency than sotorasib/adagrasib in preclinical models; phase 1 ORR 53% in NSCLC. Krascendo 1 (vs sotorasib or adagrasib, previously treated NSCLC) met PFS and OS. Krascendo 2 tests divarasib + pembrolizumab ± chemotherapy first line. FDA orphan designation 2026; filing expected.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-06
- Code: GDC-6036
- Modality: Small-molecule inhibitor (KRAS G12C)
- Mechanism: Covalent KRAS G12C (OFF-state) inhibitor.

## Sources

- Roche Krascendo 1 release: https://www.roche.com/media/releases/med-cor-2026-07-02

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- trials: [A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip](https://onco.cc/trials/nct06793215/), [A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par](https://onco.cc/trials/nct05789082/), [A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese](https://onco.cc/trials/nct07541170/), [Krascendo 1](https://onco.cc/trials/krascendo-1/)
- biomarkers: [KRAS G12C](https://onco.cc/biomarkers/kras-g12c/)
- roadmaps: [Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall](https://onco.cc/roadmaps/targeted-therapy-roadmap/)
- pathways: [Non-small cell lung cancer (KEGG map)](https://onco.cc/pathways/nsclc-signalling/)

---
JSON: https://onco.cc/api/v1/entities/divarasib.json